Addressing the Unanswered Questions in Myopia Management

Clinical Report: Addressing the Unanswered Questions in Myopia Management

Background

Myopia is a growing public health concern, particularly among children. Evidence-based myopia management is essential for optimizing patient outcomes, yet many questions remain unanswered regarding the most effective treatment strategies and patient selection criteria.

Data Highlights

Treatment	Age Range	Max Myopia
Myopia control spectacles	8-13 years	1.50 DC
Myopia control soft contact lenses	8-12 years	0.75 DC
Topical low-concentration atropine	5-13 years	2.50 DC
Orthokeratology	7-16 years	3.50 DC

Key Findings

Atropine is effective for younger children and higher myopia levels.
Orthokeratology shows efficacy for higher myopia, astigmatism, and anisometropia.
Most treatments exhibit similar efficacy in reducing axial elongation.
There is a lack of comparative studies on myopia control interventions.
Determining the suitability of treatments for individual patients remains challenging.

Clinical Implications

Clinicians should be aware of the limitations of current evidence when selecting myopia management strategies.

Conclusion

The management of myopia requires a nuanced understanding of treatment options and patient characteristics.